Search bioRxiv⌕ Search

Biology subjects

McCraw, A.

Publications and source records attributed to McCraw, A..

2 recordsLinked to original sources

Tuning antibody stability and function by rational designs of framework mutations

Artificial intelligence and machine learning models have been developed to engineer antibodies for specific recognition of antigens, however these approaches often focus on the antibody complementarity determining region (CDR) whilst ignoring the immunoglobulin framework (FW) which provides structural rigidity and support for the flexible CDR loops. Here we present an integrated computational-experimental workflow, combining static structure analyses, molecular dynamics simulations and in vitro physicochemical and functional assays to generate rational designs of FW mutations for modulating antibody stability and activity. We first showed that recent antibody-specific language models lacked insights in FW mutagenesis, in comparison to approaches which utilised antibody structure information. Using the widely-used breast cancer therapeutic trastuzumab as a use case, we designed stabilising mutants which were distal to the CDR and preserved the antibodys functionality to engage its cognate antigen (HER2) and induce antibody-dependent cellular cytotoxicity (ADCC). Interestingly, guided by local backbone motions predicted using molecular dynamics simulations, we designed a FW mutation on the trastuzumab light chain which retained antigen-binding effects but lost Fab-mediated and Fc-mediated effector functions. This highlighted effects of FW on immunological functions engendered in distal areas of the antibody, and the importance to consider attributes other than binding affinity when assessing antibody function. Our approach incorporates interdomain dynamics and distal effects between FW and the Fc domains, expands the scope of antibody engineering beyond the CDR, and underscores the importance of a holistic perspective that considers the entire antibody structure as a whole in optimising antibody stability, developability and function.

immunology↗

Regulatory T cell activation triggers specific changes in glycosylation associated with Siglec-1-dependent inflammatory responses

Siglec-1 is a macrophage lectin-like receptor that mediates sialic acid-dependent cellular interactions. It was shown previously to promote inflammation in autoimmune disease through suppressing the expansion of regulatory T cells (Tregs). We have investigated the molecular basis for Siglec-1 binding to these cells using in vitro-induced Tregs. Siglec-1 binding was strongly upregulated on activated cells, but lost under resting conditions. Glycosylation changes that affect Siglec-1 binding were studied by comparing activated and resting Tregs using RNA-Seq, glycomics, proteomics and binding of selected antibodies and lectins. A proximity labelling and proteomics strategy identified 49 glycoproteins expressed by activated Tregs that may function as Siglec-1 counter-receptors. These represent [~]5% of the total membrane protein pool and were mainly related to T cell activation and proliferation. We demonstrate that several of these counter-receptors are upregulated following activation of Tregs and provide initial evidence that their altered glycosylation may also be important for Siglec-1 binding.

immunology↗